

## Register of declared private, professional, commercial and other interests

Please refer to the above guidance before completing this form. All fields **MUST** be completed. Where you have no relevant interests in a particular section, please enter '**None**' in the register entry.

<b>Please list all NC3Rs Board/Panels that you are a member of and your position:</b> e.g. member NC3Rs Board, Chair Grant Assessment Panel, member CRACK IT Challenge Panel, etc	NC3Rs Impact Working Group
---	----------------------------

	Member interests	
<b>Name</b>	Mark Coles	
<b>Employer</b>	University of Oxford	
<b>Position</b>	Kennedy Professor of Immunology, Kennedy Institute of Rheumatology, NDORMS	
<b>Personal remuneration</b> (e.g. employment, pensions, consultancies, directorships, honoraria) SEE GUIDANCE SECTION 1	University of Oxford  Consultancy F. Hoffmann-La Roche AG  Consultancy Mestag Therapeutics  Consultancy Simomics Ltd	
<b>Shareholdings and financial interests in companies</b>  SEE GUIDANCE SECTION 2	Shareholder Mestag Therapeutics Shareholder Simomics Ltd Shareholder Lightox Ltd	
<b>Sources of research income</b> (over £50k per grant)  SEE GUIDANCE SECTION 3	2020-2023	Computational Pharmacology, Arthritis Therapy Acceleration Program (225, 000)
	2020-2022	Implementing Immune Cell Trafficking Models Approaches to Enhance the Understanding of the Dosing of Cancer Immunotherapeutics, Roche AG (210,000)
	2019-2021	Predicting therapeutic biomarkers for cancer patient stratification and personalised treatment strategies: A novel data analysis platform combining <b>TOP</b> ological analysis and <b>M</b> athematical modelling <b>AP</b> roaches (TOP-MAP), Emmerson Collective, (£200,000)
	2019-2022	<i>In-silico</i> Modelling for Analyzing the Determinants of Vaccine Success, IMV (£517,386)
	2019-2020	Inhibiting the activation of pathogenic arthritic fibroblasts through a first-in-class inhibitor targeting the CLIC5 chloride channel, Lab282 (£417,000)
	2019-2024	Therapeutic targeting of fibroblast subsets in inflammatory arthritis, Medical Research Council,

	<p>(£2,482,603)</p> <p>2019-2021 The joint atlas: A cellular map of key anatomical structures in the human synovial joint during development and in healthy adults, Medical Research Council, (£567,184)</p> <p>2019-2022 Computational framework for T cell trafficking and dynamics in anti-tumour immune responses, Celgene Fellowship (£485,00)</p> <p>2019-2022 Inhibiting tissue damage in rheumatoid arthritis through a first in class inhibitor of Tetraspanin-15, Lab282 (£485,000)</p> <p>2017-2022 Personal Support, Kennedy Trust Rheumatology Research (£575,000)</p> <p>2019-2020 Tissue Digestion and Cellular Pathology Platform, Kennedy Trust Rheumatology Research (£179,000)</p> <p>2020-2024 Rheumatoid Arthritis Centre of Excellence, Versus Arthritis (Studentship Network)</p>
<p><b>Major academic collaborations</b></p> <p>SEE GUIDANCE SECTION 4</p>	<p>Christopher Buckley Andrew Filer Sanjiv Luther Tom Cupedo Burkhard Ludewig</p>
<p><b>Unremunerated interests</b> (e.g. involvements with and memberships of biomedical, pharmaceutical, and similar activities/organisations) SEE GUIDANCE SECTION 5</p>	<p>Kennedy Institute of Rheumatology, University of Oxford</p> <p>Official Fellow and Theme Lead for Life Science Reuben College</p> <p>Honorary Professor, Department of Biology, University of York</p> <p>Congress Secretary and Member of British Society of Immunology</p> <p>Member of the Royal Microscopy Society</p> <p>Member of the Pathology Society of Great Britain</p> <p>Member of the Royal Society of Biology</p> <p>Member International Society of Pharmacovigilance</p> <p>Director Simomics</p> <p>Director Lightox</p> <p>Scientific Advisory Board MesTag Therapeutics</p>
<p><b>Political / pressure group associations</b></p> <p>SEE GUIDANCE SECTION 6</p>	<p>None</p>
<p><b>Family</b> (declare any potential conflicts that may arise out of any known family interests and indicate which section (1 – 6) would apply.) SEE GUIDANCE SECTION 7</p>	<p>Father; Shareholder AstraZeneca PLC</p>

## Declaration

I have read the ['MRC Code of Practice for Members of Council and Boards and MRC Policy on Declarations of Interests'](#) and agree to abide by the principles and terms of the Code.

I undertake to declare at meetings on NC3Rs business any private, professional, commercial, financial, political or other interests that might be perceived to conflict with the NC3Rs interests and which have not been listed above. I accordingly agree to update this written declaration on an annual basis over the term of my appointment and provide further interim updates as circumstances change.

I note and accept that the NC3Rs will hold the details I have provided and that these details will be available for public inspection and are subject to inspection by auditors. I note and accept that the information provided here will be published (other than any sections I have identified as being confidential) on the NC3Rs website and that it and will be retained in line with the NC3Rs retention and disposal policy for records.

I hereby declare that the information and record(s) submitted as indicated above is true and correct to the best of my knowledge and belief.

Accept